Canaccord Genuity Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $116

Benzinga Newsdesk www.benzinga.com Positive 87.1%

Neg 0% Neu 0% Pos 87.1%

Canaccord Genuity analyst Whitney Ijem maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $104 to $116.